ShedRx vs Candor Rx
Two GLP-1 desks, one scoreboard. We put ShedRx and Candor Rx head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
ShedRx takes this head-to-head.
ShedRx scores 87 to 70 on our six-factor Brief Score — A weight-focused program with a low tracked tirzepatide rate and an oral/sublingual route for the needle-averse.
That doesn't make Candor Rx a bad call — it's best for cost-focused buyers who want flat, any-dose compounded glp-1 pricing with no dose upcharges. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| ShedRx | Candor Rx | |
|---|---|---|
| Brief Score | 87/100 (B+) | 70/100 (C) |
| Semaglutide | $199/mo | From $99/mo (all doses, compounded) |
| Tirzepatide | $299/mo | From $149/mo (all doses, compounded) |
| Coverage | Not disclosed | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
| On the tracker | Fallingprice falling | Newnew to the tracker, no prior reading |
ShedRx: Competitive tirzepatide rate trimmed further this cycle — cheapest tirz among our partner desks.
Candor Rx: New to the tracker on 1 August 2026. The published line reads From $99/mo (all doses, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.